Efficacy and safety of levetiracetam 1000–3000mg/day in patients with refractory partial-onset seizures: a multicenter, open-label single-arm study
- 1 January 2005
- journal article
- clinical trial
- Published by Elsevier in Epilepsy Research
- Vol. 63 (1) , 1-9
- https://doi.org/10.1016/j.eplepsyres.2004.09.005
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- The KEEPER™ trial: levetiracetam adjunctive treatment of partial-onset seizures in an open-label community-based studyEpilepsy Research, 2003
- An open-label study of levetiracetam at individualised doses between 1000 and 3000 mg day−1 in adult patients with refractory epilepsySeizure, 2003
- Efficacy and Tolerability of Levetiracetam 3000 mg/d in Patients with Refractory Partial Seizures: A Multicenter, Double‐Blind, Responder‐Selected Study Evaluating MonotherapyEpilepsia, 2000
- Levetiracetam for partial seizuresNeurology, 2000
- Pharmacokinetic profile of levetiracetamPharmacology & Therapeutics, 2000
- Evidence for a unique profile of levetiracetam in rodent models of seizures and epilepsyPublished by Elsevier ,1998
- Development and Cross‐Cultural Translations of a 31‐Item Quality of Life in Epilepsy InventoryEpilepsia, 1998
- Monotherapy Clinical Trials of New Antiepileptie Drugs: Design, Indications, and ControversiesEpilepsia, 1997
- The novel antiepileptic drug levetiracetam (ucb L059) appears to act via a specific binding site in CNS membranesEuropean Journal of Pharmacology, 1995
- Proposal for Revised Classification of Epilepsies and Epileptic SyndromesEpilepsia, 1989